Cidofovir
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
moxetumomab pasudotox
antibody-cytotoxin conjugate, anti-CD22, Pseudomonas exotoxin A fusion · anticancer
antibody-cytotoxin conjugate, anti-CD22, Pseudomonas exotoxin A fusionanticancer
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- CidofovirSevereDatabaseDDInter
- DeferasiroxSevereDatabaseDDInter
- DiatrizoateSevereDatabaseDDInter
- EverolimusSevereDatabaseDDInter
Mechanism
Moxetumomab pasudotox is a CD22-directed antibody fused to a truncated form of the Pseudomonas exotoxin A. Upon entering cells, the exotoxin inhibits protein synthesis through ADP-ribosylation of elongation factor 2 and causes cell death.
Indications
relapsed or refractory hairy cell leukemia
Drug interactions
Deferasirox
Severe
Database
Clinical effect not specified
Source: DDInter
Diatrizoate
Severe
Database
Clinical effect not specified
Source: DDInter
Everolimus
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Human Cytomegalovirus Immune Globulin
Severe
Database
Clinical effect not specified
Source: DDInter
Inotersen
Severe
Database
Clinical effect not specified
Source: DDInter
Iodipamide
Severe
Database
Clinical effect not specified
Source: DDInter
Iodixanol
Severe
Database
Clinical effect not specified
Source: DDInter
Iohexol
Severe
Database
Clinical effect not specified
Source: DDInter
Iopamidol
Severe
Database
Clinical effect not specified
Source: DDInter
Iopromide
Severe
Database
Clinical effect not specified
Source: DDInter
Iothalamic Acid
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about moxetumomab pasudotox
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team